Compare Kyowa Kirin Co., Ltd. with Similar Stocks
Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Low Debt Company with Strong Long Term Fundamental Strength
3
With a growth in Net Profit of 95.14%, the company declared Outstanding results in Dec 25
4
With ROE of 7.50%, it has a fair valuation with a 1.42 Price to Book Value
5
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,258,106 Million (Large Cap)
19.00
NA
0.04%
-0.28
8.17%
1.41
Revenue and Profits:
Net Sales:
118,467 Million
(Quarterly Results - Mar 2026)
Net Profit:
12,034 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.18%
0%
-3.18%
6 Months
-3.94%
0%
-3.94%
1 Year
6.23%
0%
6.23%
2 Years
-11.71%
0%
-11.71%
3 Years
-22.72%
0%
-22.72%
4 Years
-15.69%
0%
-15.69%
5 Years
-30.57%
0%
-30.57%
Kyowa Kirin Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.31%
EBIT Growth (5y)
11.70%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.57
Tax Ratio
30.50%
Dividend Payout Ratio
48.41%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
16.11%
ROE (avg)
7.78%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.42
EV to EBIT
10.27
EV to EBITDA
8.18
EV to Capital Employed
1.56
EV to Sales
2.11
PEG Ratio
1.90
Dividend Yield
0.04%
ROCE (Latest)
15.16%
ROE (Latest)
7.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
118,467.00
104,725.00
13.12%
Operating Profit (PBDIT) excl Other Income
24,880.00
15,638.00
59.10%
Interest
2,270.00
141.00
1,509.93%
Exceptional Items
0.00
0.00
Consolidate Net Profit
12,034.00
6,167.00
95.14%
Operating Profit Margin (Excl OI)
145.50%
91.00%
5.45%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 13.12% vs -0.80% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 95.14% vs -57.85% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
496,826.00
495,558.00
0.26%
Operating Profit (PBDIT) excl Other Income
128,419.00
116,646.00
10.09%
Interest
1,539.00
709.00
117.07%
Exceptional Items
-14,627.00
-15,135.00
3.36%
Consolidate Net Profit
67,040.00
59,870.00
11.98%
Operating Profit Margin (Excl OI)
205.90%
185.40%
2.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.26% vs 12.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.98% vs -26.26% in Dec 2024
About Kyowa Kirin Co., Ltd. 
Kyowa Kirin Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






